Phase 1/II, Safety and Immunogenicity Study of AERAS-404 in BCG-Primed Infants (C-015-404)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01861730 |
Recruitment Status
:
Completed
First Posted
: May 24, 2013
Last Update Posted
: April 9, 2018
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Tuberculosis | Biological: AERAS-404 Biological: Placebo | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 243 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Prevention |
Official Title: | Phase 1/II, Safety and Immunogenicity Study of a Recombinant Protein Tuberculosis Vaccine (AERAS-404) in BCG-Primed Infants |
Actual Study Start Date : | July 1, 2013 |
Actual Primary Completion Date : | December 22, 2017 |
Actual Study Completion Date : | December 22, 2017 |
Arm | Intervention/treatment |
---|---|
Experimental: Cohort 1 Aeras404 (5ug H4/100nmol IC31) or Placebo
1 Dose; Subject ≥ 168 to ≤ 196 days of age
|
Biological: AERAS-404
AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.
Other Name: H4
Biological: Placebo
Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).
Other Name: Tris buffered saline
|
Experimental: Cohort 2 AERAS-404 (5ug H4/500nmol IC31) or Placebo
1 Dose; Subject ≥ 168 to ≤ 196 days of age
|
Biological: AERAS-404
AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.
Other Name: H4
Biological: Placebo
Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).
Other Name: Tris buffered saline
|
Experimental: Cohort 3A AERAS-404 (5ug H4/500nmol IC31) or Placebo
2 Doses; Subject ≥ 168 to ≤ 189 days of age
|
Biological: AERAS-404
AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.
Other Name: H4
Biological: Placebo
Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).
Other Name: Tris buffered saline
|
Experimental: Cohort 3B AERAS-404 (15ug H4/500nmol IC31) or Placebo
2 Doses; Subject ≥ 168 to ≤ 189 days of age
|
Biological: AERAS-404
AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.
Other Name: H4
Biological: Placebo
Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).
Other Name: Tris buffered saline
|
Experimental: Cohort 4 AERAS-404 (15ug H4/500nmol IC31) or Placebo
3 Doses; Subject ≥ 84 to ≤ 98 days of age
|
Biological: AERAS-404
AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.
Other Name: H4
Biological: Placebo
Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).
Other Name: Tris buffered saline
|
Experimental: Cohort 5 AERAS-404 (50ug H4/500nmol IC31) or Placebo
3 Doses; Subject ≥ 84 to ≤ 98 days of age
|
Biological: AERAS-404
AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.
Other Name: H4
Biological: Placebo
Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).
Other Name: Tris buffered saline
|
Experimental: Cohort 6 AERAS-404 (dose level pending) or Placebo
3 Doses; Subject ≥ 64 to ≤ 83 days of age
|
Biological: AERAS-404
AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.
Other Name: H4
Biological: Placebo
Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).
Other Name: Tris buffered saline
|
- Investigate the safety of AERAS-404 in HIV-uninfected, HIV-unexposed, BCG-primed infants. [ Time Frame: Subjects will be followed for up to 1 year and 4 months. ]Adverse Events and Serious Adverse Events (SAE) will be collected on subjects throughout their participation in the study. Solicited adverse events are captured 28 days post each vaccination. Evaluation of the safety profile of AERAS-404 will be performed using data from all subjects who received at least one dose and has 7 days of safety data, and will be summarized by cohort and treatment group. The number (percentage) of subjects with any adverse event (including solicited, unsolicited, and serious adverse events) will be summarized by Medical Dictionary for Regulatory Activities (MedDRA) system organ class and Preferred Term. Additional summaries will present the number (percentage) of subjects with any adverse events by severity and by relationship to study vaccine; parameters evaluable by the Aeras 404 Pediatric Toxicity Table provided in the protocol, will be summarized by severity corresponding to Toxicity Grade, as appropriate.
- Investigate the safety of a 3-dose AERAS-404 regimen in HIV-uninfected, HIV-unexposed, BCG-primed infants [ Time Frame: Subjects will be followed for up to 1 year and 4 months. ]The number and percentage of subjects who are enrolled into the three-dose regimen (Cohorts 4-6) with solicited and unsolicited AEs (including serious adverse events [SAEs], local and systemic reactions, and clinical laboratory values or vital sign values recorded as newly abnormal following study vaccination) recorded post-vaccination will be summarized to address the secondary safety objective of the study. Subjects in Cohorts 4 and 5 will be followed for : 1 year and 3 months, Cohort 6: 1 year 4 months and Solicited adverse events are captured 28 days post each vaccination.
- Assess the immunogenicity of a 3-dose AERAS-404 regimen in HIV-uninfected, HIV-unexposed, BCG-primed infants. [ Time Frame: Subjects will be followed for up to 1 year and 4 months. ]T-cell response, as measured by Intracellular Cytokine Staining (ICS) following stimulation with peptide pools spanning the vaccine antigens, will be used to assess immunogenicity.
- Select an appropriate dose regimen for AERAS-404 in HIV-uninfected, HIV-unexposed, BCG-primed infants. [ Time Frame: After all subjects in Cohorts 4 and 5 have completed Study Day 126, the safety and immunogenicity data from these Cohorts will be evaluated. The data will inform the decision on the study vaccine dose for Cohort 6. ]Safety and immunogenicity analyses will be reviewed for the selection of the appropriate dose regimen
- Explore interactions between AERAS-404 and EPI vaccines. [ Time Frame: Antibody concentration blood samples taken when subjects reach 12 months of age for all Cohorts and in addition, 28 post second study vaccine dose (Study Day 56) for subjects in Cohort 6 only. ]Antibody concentration levels at 12 months of age for all Cohorts, and in addition at 28 days post second study vaccine dose (Study Day 56) for Cohort 6 will be presented. Summaries will include antibody titers to Tetanus toxoid vaccine (tetanus; given at 6, 10, 14 weeks of age), and Haemophilus influenza B conjugate vaccine (given at 6, 10, 14 weeks of age). Responses to other EPI vaccines may also be assessed.
- Assess the immunogenicity of a 2-dose AERAS-404 regimen in HIV-uninfected, HIV-unexposed, BCG-primed infants. [ Time Frame: Subjects will have Immunology samples taken at multiple time points for up to 1 year and 4 months. ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 64 Days to 196 Days (Child) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | Yes |
INCLUSION CRITERIA
-
Age at time of entry:
Cohorts 1 to 6
- Cohorts 1 and 2: ≥ 168 to ≤ 196 days
- Cohorts 3A and 3B: ≥ 168 to ≤ 189 days
- Cohorts 4 and 5: ≥ 84 to ≤ 98 days (≥ 2 weeks after receipt of EPI vaccine doses at 10 weeks of age)
- Cohort 6 - coincident with EPI vaccine doses at 10 weeks of age (≥ 64 to ≤ 83 days of age)
- Source documentation of birth weight ≥ 2.5 kg.
- Documented BCG vaccination within 72 hours of birth.
- Documented receipt of all age-appropriate EPI vaccines, except Rotavirus, for Cohorts 4 to 6 (see Appendix II).
- Source documentation of a negative HIV status in the mother, from any time during pregnancy with this child through randomization.
- Documentation of infant HIV negative exposure or infection status with negative HIV ELISA and HIV DNA PCR tests.
- Parent or legal guardian able and willing to provide signed informed consent.
- Participant/parent/legal guardian able to attend all scheduled visits and to comply with all trial procedures.
EXCLUSION CRITERIA
- History of TB exposure in household or non-household contact.
- History/Evidence of TB disease or infection.
- Quantiferon positive.
- Prior TST test.
- Any one of Anemia, Neutropenia, Thrombocytopenia, SGPT (ALT), SGOT (AST) or Creatinine ≥ Grade 2
- Receipt of a live vaccine within 28 days prior to randomization.
- Receipt or planned receipt of any investigational vaccine.
- Known or suspected congenital immunodeficiency.
- Receipt of immunosuppressive therapy or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).
- Known or suspected autoimmune disease
- Hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to a vaccine containing any of the same substances as the vaccine used in the trial.
- Participation in another clinical trial for an investigational product (IP).
- Bleeding disorder or receipt of anticoagulants in the 3 weeks preceding randomization, contraindicating IM vaccination.
- Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with trial conduct or completion.
-
Febrile illness (temperature ≥ 100.4°F [≥ 38.0°C]) within 24 hours prior to randomization.
Note: A subject may enroll after recovery from febrile illness if the subject is still within the age window.
- Systemic antibiotic use within 48 hours prior to randomization.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01861730
South Africa | |
PHRU, Chris Hani Baragwanath Hospital | |
Johannesburg, Guateng, South Africa, 2091 | |
Shandukani Research | |
Johannesburg, Hillbrow, South Africa, 2001 | |
KID-CRU, Tygerberg Hospital | |
Cape Town, Tygerberg, South Africa, 7505 | |
South African TB Vaccine Initiative (SATVI) | |
Worcester, South Africa |
Study Director: | Ann Ginsberg, MD, PhD | Aeras | |
Principal Investigator: | Avy Violari, MD | Perinatal HIV Research Unit |
Responsible Party: | Aeras |
ClinicalTrials.gov Identifier: | NCT01861730 History of Changes |
Other Study ID Numbers: |
C-015-404/ IMPAACT P1113 U01AI068632 ( U.S. NIH Grant/Contract ) C-015-404 ( Other Identifier: Aeras ) |
First Posted: | May 24, 2013 Key Record Dates |
Last Update Posted: | April 9, 2018 |
Last Verified: | April 2018 |
Keywords provided by Aeras:
BCG Vaccinated HIV Negative |
Additional relevant MeSH terms:
Tuberculosis Mycobacterium Infections Actinomycetales Infections Gram-Positive Bacterial Infections Bacterial Infections |